Results 51 to 60 of about 212,526 (280)
Blood Advances, 2022 Bruton’s tyrosine kinase inhibitors (BTKis) have altered the treatment landscape for chronic lymphocytic leukemia (CLL) by offering effective and well-tolerated therapeutic options.
F. Awan +11 more
semanticscholar +1 more source
Current understanding of tyrosine kinase BMX in inflammation and its inhibitors
Burns & Trauma, 2014 Tec family kinases, which include tyrosine kinase expressed in hepatocellular carcinoma (TEC), Bruton's tyrosine kinase (BTK), interleukin (IL)-2-inducible T-cell kinase (ITK), tyrosine-protein kinase (TXK), and bone marrow tyrosine kinase on chromosome ...
Le Qiu, Fei Wang, Sheng Liu, Xu-Lin Chen
doaj +1 more source
Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia [PDF]
, 2010 Mutations in Bruton's tyrosine kinase (BTK) gene are responsible for X-linked agammaglobulinemia (XLA), which is characterized by recurrent bacterial infections, profound hypogammaglobulinemia, and decreased numbers of mature B cells in peripheral blood.
OLIVEIRA JÚNIOR, E.B. +4 more
core +2 more sources
eJHaem, 2021 ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi +9 more
doaj +1 more source
A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis
Journal of Clinical Investigation, 2023 BACKGROUND IgE-mediated anaphylaxis is a potentially fatal systemic allergic reaction for which there are no currently FDA-approved preventative therapies.
R. V. Suresh +6 more
semanticscholar +1 more source
Nature Communications, 2020 PROTACs have emerged as promising therapeutic agents but their cellular uptake is often inefficient. Here, the authors show that reversible covalent warhead chemistry improves PROTAC intracellular accumulation and target engagement, and develop a dual ...
Wen-Hao Guo +18 more
doaj +1 more source
Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor [PDF]
, 2014 A number of Bruton's tyrosine kinase (BTK) inhibitors are currently in development, yet it has been difficult to visualize BTK expression and pharmacological inhibition in vivo in real time.
Kim, Eunha +4 more
core +1 more source
Blood Cancer Journal, 2022 Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton’s tyrosine kinase (BTK), was designed as an alternative strategy to treat ibrutinib-resistant disease that develops due to C481 kinase domain mutations. The clinical activity of pirtobrutinib has
Burcu Aslan +9 more
semanticscholar +1 more source
Haematologica, 2019 Tyrosine kinases have been implicated in promoting tumorigenesis of several human cancers. Exploiting these vulnerabilities has been shown to be an effective anti-tumor strategy as demonstrated for example by the Bruton's tyrosine kinase (BTK) inhibitor,
Debora Soncini +24 more
doaj +1 more source
Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity [PDF]
, 2005 During B-cell development in the mouse, Bruton tyrosine kinase (Btk) and the adaptor protein SLP-65 (Src homology 2 [SH2] domain-containing leukocyte protein of 65 kDa) limit the expansion and promote the differentiation of pre-B cells.
Dingjan, G.M. (Gemma) +5 more
core +3 more sources